Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Three Stocks With Estimated Undervaluation Worth Considering In February 2025

In This Article:

In February 2025, global markets are experiencing a mix of geopolitical tensions and economic uncertainty, with U.S. stocks facing downward pressure due to concerns about consumer spending and potential new tariffs. Amid this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer resilience or growth potential despite broader market challenges.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

MINISO Group Holding (NYSE:MNSO)

US$20.68

US$41.04

49.6%

Vimi Fasteners (BIT:VIM)

€0.96

€1.91

49.8%

OSAKA Titanium technologiesLtd (TSE:5726)

¥1860.00

¥3696.77

49.7%

Power Wind Health Industry (TWSE:8462)

NT$113.50

NT$226.14

49.8%

CD Projekt (WSE:CDR)

PLN220.70

PLN441.19

50%

Vestas Wind Systems (CPSE:VWS)

DKK102.40

DKK204.54

49.9%

Thunderbird Entertainment Group (TSXV:TBRD)

CA$1.69

CA$3.36

49.6%

Hanwha Aerospace (KOSE:A012450)

₩680000.00

₩1356955.59

49.9%

CGN Mining (SEHK:1164)

HK$1.43

HK$2.85

49.8%

Shenzhen Anche Technologies (SZSE:300572)

CN¥18.69

CN¥37.15

49.7%

Click here to see the full list of 925 stocks from our Undervalued Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Almirall

Overview: Almirall, S.A. is a biopharmaceutical company focused on the purchase, manufacture, storage, and sale of skin-health medicines across Europe, the Middle East, the United States, Asia, and Africa with a market cap of €2.08 billion.

Operations: Almirall's revenue primarily stems from its activities in the biopharmaceutical sector, specifically through the production and distribution of skin-health medications across various regions including Europe, the Middle East, the United States, Asia, and Africa.

Estimated Discount To Fair Value: 36.8%

Almirall is trading at €9.76, significantly below its estimated fair value of €15.43, indicating potential undervaluation based on cash flows. Recent earnings show a turnaround with net income of €10.15 million compared to a loss last year, and sales growth from €894.52 million to €985.72 million in 2024. The company forecasts 10%-13% sales growth for 2025 and expects profitability within three years, despite slower revenue growth than the broader market expectations.

BME:ALM Discounted Cash Flow as at Feb 2025
BME:ALM Discounted Cash Flow as at Feb 2025

Norsk Hydro

Overview: Norsk Hydro ASA is involved in global power production, bauxite extraction, alumina refining, aluminium smelting, and recycling activities with a market cap of NOK131.57 billion.